<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> with <z:hpo ids='HP_0001085'>papilledema</z:hpo> has been reported in renal patients, but a survey of the literature suggests that the incidence rate is low </plain></SENT>
<SENT sid="1" pm="."><plain>We present reports of 15 of approximately 1,670 patients with <z:e sem="disease" ids="C0851590" disease_type="Disease or Syndrome" abbrv="">renal disorders</z:e>, who were treated with growth hormone for impaired growth and subsequently developed symptoms and/or signs of intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The male:female ratio was 6.5:1, and the median age was 12 years </plain></SENT>
<SENT sid="3" pm="."><plain>The median duration of growth hormone treatment before <z:hpo ids='HP_0003674'>onset</z:hpo> of symptoms or signs was 13 weeks </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> but 2 patients were symptomatic </plain></SENT>
<SENT sid="5" pm="."><plain>In the patients in whom growth hormone therapy is known to have been discontinued, the symptoms and signs of intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> abated </plain></SENT>
<SENT sid="6" pm="."><plain>At least 4 of these patients experienced a recurrence when re-exposed to growth hormone </plain></SENT>
<SENT sid="7" pm="."><plain>Many of the affected patients presented with predisposing conditions, but growth hormone appears to have been the precipitating factor </plain></SENT>
<SENT sid="8" pm="."><plain>Prospective funduscopic evaluation may be warranted in patients with <z:e sem="disease" ids="C0851590" disease_type="Disease or Syndrome" abbrv="">renal disorders</z:e> who are receiving growth hormone </plain></SENT>
</text></document>